systems mab1139 500  (R&D Systems)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Chemoradiotherapy facilitates siglec-10 + /siglec-9 + macrophage-mediated impairment of CD24 + /MUC16 + tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer

doi: 10.1007/s00262-026-04355-6

Figure Lengend Snippet: CCRT Induces Upregulation of Siglec-10 and Siglec-9 in Macrophages and Promotes M2 Polarization A Gene expression feature plots for the expression of Siglec-10. B Violin plots for the expression of Siglec-10 in CCRT and TN groups. C Gene expression feature plots for the expression of Siglec-9. D Violin plots for the expression of Siglec-9 in CCRT and TN groups. E Circos plot for the potential interactions among ten major cell types via CD24 and Siglec-10 predicted by CellChat. F Circos plot for the potential interactions among ten major cell types via MUC16 and Siglec-9 predicted by CellChat. G UMAP plots for the cell distribution in the macrophage subgroup analysis. H UMAP plots for macrophages from TN and CCRT groups. I Distribution of macrophage subpopulations in CCRT and TN groups. J–K Violin plots for the expression of Siglec-10 (J) and Siglec-9 (K) in macrophages subpopulation analysis of CCRT and TN groups. L-O Flow cytometry for the expression levels of Siglec-10 (L-M) and Siglec-9 (N–O)in macrophages from cervical cancer tissues before and after CCRT. For (B), (D), (J), (K), (M) and (O), data are presented as mean ± SEM. Paired two-tailed t tests were performed. * p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; TN, treatment-naïve

Article Snippet: Subsequently, the sections were blocked with antibody diluent (Dako) for 1 h, followed by incubation overnight at 4 °C with the following primary antibodies: mouse anti-human CD68 (Invitrogen, MA5-13324, 1:100), anti-human Siglec-10-APC (Biolegend, clone 5G6, AB_11203899, 1:100), rabbit anti-human Siglec-9 (Proteintech, 1:5000), anti-human CD24-BV421 (Biolegend, clone ML5, AB_10915556, 1:200), and anti-human MUC16-Alexa Fluor 594 (R&D SYSTEMS, FAB56091T, 1:200).

Techniques: Gene Expression, Expressing, Flow Cytometry, Two Tailed Test

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Chemoradiotherapy facilitates siglec-10 + /siglec-9 + macrophage-mediated impairment of CD24 + /MUC16 + tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer

doi: 10.1007/s00262-026-04355-6

Figure Lengend Snippet: IL-4 Stimulation Increases PD-L2 Expression in Siglec-10 + /Siglec-9 + Macrophages A The proportions of Siglec-10 + macrophage, Siglec-9 + macrophage, Siglec-10 + /Siglec-9 + macrophage and Siglec-10 − Siglec-9 − Macrophage in the CCRT and TN groups. B Volcano plots for the differential gene expression between Siglec-10 + /Siglec-9 + macrophage and Siglec-10 − /Siglec-9 − macrophage. C GSEA for the PD-L2 pathway of Siglec-10 + /Siglec-9 + macrophage relative to Siglec-10 + /Siglec-9 + macrophage. D Boxplots for IL-4 expression levels in different cell phenotypes in CCRT and TN. E Boxplots for GATA3 expression levels in T cells in CCRT and TN. F–H Macrophages were treated with IL-4 (F), and flow cytometry (G, H) was used to detect PD-L2 expression in macrophages. I-J Flow cytometry was used to assess the expression of Siglec-10 (I) and Siglec-9 (J) in macrophages from the IL-4 treated and untreated groups.For (A), (D) and (E), data are mean ± SEM. Paired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001.For (H), (I) and (J), data are presented as mean ± SEM. Unpaired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; TN, treatment-naïve; GSEA, Gene Set Enrichment Analysis

Article Snippet: Subsequently, the sections were blocked with antibody diluent (Dako) for 1 h, followed by incubation overnight at 4 °C with the following primary antibodies: mouse anti-human CD68 (Invitrogen, MA5-13324, 1:100), anti-human Siglec-10-APC (Biolegend, clone 5G6, AB_11203899, 1:100), rabbit anti-human Siglec-9 (Proteintech, 1:5000), anti-human CD24-BV421 (Biolegend, clone ML5, AB_10915556, 1:200), and anti-human MUC16-Alexa Fluor 594 (R&D SYSTEMS, FAB56091T, 1:200).

Techniques: Expressing, Gene Expression, Flow Cytometry, Two Tailed Test

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Chemoradiotherapy facilitates siglec-10 + /siglec-9 + macrophage-mediated impairment of CD24 + /MUC16 + tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer

doi: 10.1007/s00262-026-04355-6

Figure Lengend Snippet: M2-like Macrophages Suppress T Cell Function via PD-L2 Following CCRT A UMAP plots for the cell distribution in macrophages and CD8 + T cells subgroup analysis. B Dotplot for marker genes of different cell types of the scRNA-seq data. C Distribution of macrophages and CD8 + T cells subpopulations in CCRT and TN groups of patients with cervical cancer. D Violin plots for the expression of PD-L2 in CCRT and TN in macrophage subpopulations. E Violin plots for the expression of PDCD1 in CCRT and TN in CD8 + T cells subpopulations. F–G Flow cytometry for the expression levels of PD-L2 in macrophages from cervical cancer tissues before and after CCRT. H–I Flow cytometry for the expression levels of PD-1 in T cells from cervical cancer tissues before and after CCRT. J Circos plot for the potential interactions among Siglec-10 + macrophages and T cells via PD-L2 and PD-1 predicted by CellChat. K Circos plot for the potential interactions among Siglec-9 + macrophages and T cells via PD-L2 and PD-1 predicted by CellChat. For (D) (E), (G) and (I), data are presented as mean ± SEM. Paired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; scRNA-seq, single-cell RNA sequencing; TN, treatment-naïve

Article Snippet: Subsequently, the sections were blocked with antibody diluent (Dako) for 1 h, followed by incubation overnight at 4 °C with the following primary antibodies: mouse anti-human CD68 (Invitrogen, MA5-13324, 1:100), anti-human Siglec-10-APC (Biolegend, clone 5G6, AB_11203899, 1:100), rabbit anti-human Siglec-9 (Proteintech, 1:5000), anti-human CD24-BV421 (Biolegend, clone ML5, AB_10915556, 1:200), and anti-human MUC16-Alexa Fluor 594 (R&D SYSTEMS, FAB56091T, 1:200).

Techniques: Cell Function Assay, Marker, Expressing, Flow Cytometry, Two Tailed Test, Single Cell, RNA Sequencing

Journal: Inflammation Research

Article Title: Diagnostic significance of salivary and glandular siglec-5 in Sjögren disease and non-Sjögren sicca

doi: 10.1007/s00011-026-02188-8

Figure Lengend Snippet: Salivary inflammatory markers in Sjögren disease (SjD) and non-Sjögren sicca (nSS). Salivary concentrations of (A) siglec-5/siglec-14, (B) IgA, (C) IgG, (D) nitric oxide (NO), (E) neutrophil extracellular traps (NETs), (F) interferon gamma (IFN-γ), (G) interleukin (IL)-6, and (H) IL-8 in individuals with SjD and nSS. Statistical comparisons performed using the Mann–Whitney U test. Each dot represents one patient. Horizontal lines indicate median and interquartile range

Article Snippet: Inflammatory molecules in saliva were quantified using enzyme-linked immunosorbent assay (ELISA) kits: Human siglec-5/siglec-14 DuoSet (pg/ml), Human IL-6 Quantikine HS ELISA (pg/ml), Human IL-8/CXCL8 DuoSet (pg/ml), and Human IFN-γ DuoSet (R&D Systems ® , Minneapolis, MN, USA; pg/ml); Human IgA (ng/ml) and Human IgG (ng/ml) ELISA kits (Wuhan Fine Biotech Co., Ltd., Wuhan, China); and the Nitrate/Nitrite Colorimetric Assay Kit (#780001, Cayman Chemical Co., Ann Arbor, MI, USA; μM).

Techniques: MANN-WHITNEY